Genentech and Arvinas Inc. entered into a license agreement for the development of new therapeutics using Arvinas’ PROTAC technology. The multi-year strategic license agreement encompasses multiple disease targets.
To access this subscriber-only content please log in or subscribe.
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe
If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.
Login Subscribe